Wat is de prijs voor Bellicum Pharmaceuticals, Inc. (BLCM)

Het prijs van Bellicum Pharmaceuticals, Inc. (BLCM) is $0.07475

Wat is de marktkapitalisatie voor Bellicum Pharmaceuticals, Inc. (BLCM)

Marktkapitalisatie voorBellicum Pharmaceuticals, Inc. (BLCM) is $755.60K

Bellicum Pharmaceuticals, Inc. (BLCM) Prijs en Marktkapitalisatie

Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.

Prijs voor BLCM	Aandeel B	Marktkapitalisatie van B	uitslagen
$541,885 $755.60K	NVDA	$5.478T	+724,929,046.33%
$444,011 $755.60K	AAPL	$4.488T	+593,994,561.20%
$411,882 $755.60K	GOOG	$4.163T	+551,012,739.79%
$366,474 $755.60K	MSFT	$3.704T	+490,265,723.71%
$281,102 $755.60K	AMZN	$2.841T	+376,056,071.60%

Prijs voor BLCM

Aandeel B

Marktkapitalisatie van B

uitslagen

$541,885 $755.60K